



Australian Government
Department of Health
Therapeutic Goods Administration

The TGA's approach to delays in medical device conformity assessment recertification

Due to COVID-19 pandemic and delays in EU
MDR implementation

Version 1.0, October 2020

TGA Health Safety
Regulation

Copyright

© Commonwealth of Australia 2020

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.

Contents

Background _____	4
Purpose and scope of this guidance document _____	4
Terminology _____	5
Lapsing of CADs _____	5
Suspension/cancellation/revocation of a CAD (rather than lapsing) _____	6
What the TGA expects from sponsors in relation to lapsing _____	6

Background

Changes to the medical device directive (93/42/EEC) and the IVD Directive (98/79/EC) along with the current COVID-19 pandemic, limiting international travel, have resulted in the potential inability of medical device manufacturers to maintain the currency of their conformity assessment document supporting their Australian Register of Therapeutic Goods (ARTG) inclusions for medical devices supplied in Australia.

Under the Australian legislation, medical devices included in the ARTG must have the appropriate conformity assessment procedures applied to the medical device, and sponsors must ensure the manufacturer holds the appropriate conformity assessment document for their devices.

Purpose and scope of this guidance document

The Therapeutic Goods Administration (TGA) is issuing this guidance to inform sponsors (and, where relevant, manufacturers) about the general approach the TGA will take to the lapsing of conformity assessment documents due to delays in audits due to COVID-19 and the limitations on the current number of notified bodies designated under the European Medical Devices Regulation (MDR).

This guidance applies to both overseas and Australian conformity assessment documents. However, where there is a need to distinguish between the two, we use more specific terms – see below under [Terminology](#).

This guidance is not legislative in nature and is subject to the requirements of the therapeutic goods legislation. The exact approach taken by the TGA will depend on the facts of the case and the relevant legislative provisions.



Note

Given the circumstances that have led to the changes outlined in this document, the TGA will continue to monitor developments relating to COVID-19 and its effect on the processes for conformity assessment in both Australia and internationally. As those circumstances change, the TGA will consider whether changes to the processes outlined in this guidance are necessary, and will update this guidance accordingly.

Terminology

In this guidance, the following terms are used:

- a **conformity assessment document (CAD)**: is a reference to a certificate issued by the TGA, an Australian conformity assessment body certificate, or an overseas comparable regulator conformity assessment document (see below);
- a **conformity assessment certificate (CAC)**: is a reference to a certificate issued by the TGA under s 41EE of the *Therapeutic Goods Act 1989* (the Act);
- an **overseas regulator conformity assessment document (ORCAD)**: certificate or other evidence of conformity assessment issued by an overseas regulator after that regulator is satisfied that requirements, comparable to the conformity assessment procedures, have been applied to a medical device by the manufacturer of that device;
- an **overseas regulator**: is a reference to an overseas regulator determined by the Secretary to be an overseas regulator under s 41BIB of the Act.

Lapsing of CADs

Where a CAD has **lapsed** (that is, has expired solely because of passage of time and not because of regulatory action¹), this will not result in automatic cancellation of a device entry in the ARTG. The TGA will consider, in deciding whether suspension or cancellation of a device entry is warranted, whether the sponsor has taken reasonable steps to mitigate the problem. In doing so, the TGA will consider the following matters:

- **the steps which the sponsor has taken to mitigate the situation**: for example, approaching their manufacturer to ensure they are seeking an extension or renewal of a CAD, and organising inspections, or seeking permission from the relevant overseas regulator to continue to manufacture the devices pending renewal of the CAD;
- **the timeliness of the sponsor's actions**: for example, did the sponsor act in advance of the expiry of the CAD to ensure their manufacturer would seek an extension (in the case of a CAC), or to seek recertification/renewal/extension (in the case of an ORCAD) including scheduling of manufacturer inspections?;
- **the extent to which the sponsor has kept the TGA informed**, proactively, of actions the sponsor and/or its manufacturers are taking: for example, informing the TGA promptly of the pending expiry of CADs, and of the proposed actions by the manufacturer and/or the sponsor, together with relevant supporting evidence (e.g. correspondence between the manufacturer and the sponsor);
- where applicable², whether the sponsor in the absence of a CAD has provided information to the TGA to substantiate that the devices have had the conformity assessment procedures, or requirements comparable to the conformity assessment procedures³ to the satisfaction of an overseas regulator, applied to them; and

¹ See below under Suspension/cancellation/revocation of a CAD for the approach in other instances.

² Note that some devices must have a CAC: see regulation 4.1 of the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#).

³ Under s 41FN(3)(b)(i) of the Act, it is a condition of inclusion in the ARTG that the sponsor have available sufficient information to substantiate that the conformity assessment procedures have been applied to the kind of device or that requirements, comparable to those procedures, have been applied to the kind of device to the satisfaction of an overseas regulator.

- **the presence or absence of other reasons for the lack of a current CAD:** that is, where the loss of the CAD was not due solely to the delays in audits because of COVID-19, but was due to some compliance issue on the part of the sponsor. Where the CAD was **suspended, cancelled or revoked**, rather than lapsed, see below.

If a sponsor does not provide satisfactory evidence to the TGA that it has taken reasonable steps to mitigate the expiry of the CAD, the TGA may exercise its powers of suspension or cancellation of entries in the ARTG in accordance with the Act.

Suspension/cancellation/revocation of a CAD (rather than lapsing)

Where the CAD has been suspended, cancelled, revoked or otherwise terminated due to non-compliance issues on the part of the manufacturer, the TGA will apply the terms of the Act. That is, the TGA will consider suspension or cancellation of the relevant device entries in accordance with the Act. (But note that where a CAC is revoked, the TGA must cancel the entry in the ARTG – see s 41GK of the Act).

Supply of devices that have not had conformity assessment procedures, or comparable overseas ones, applied to them, is in breach of the conditions of inclusion of the device in the ARTG. Where the relevant conformity assessment document is a CAC, the TGA may revoke or suspend the CAC in accordance with the Act.

What the TGA expects from sponsors in relation to lapsing

Sponsors (and manufacturers, if the document is a CAC) are strongly advised to notify the TGA promptly:

- if their CADs are pending expiry and there may be issues with obtaining extensions or new CADs, outlining what steps they are taking to address the problem;
- in the case of CACs: submitting an extension application to the TGA at least 6 months prior to expiry of the current CAC;
- if their CADs have already lapsed, the reasons for the lapse, and what action they are taking to address this issue.

Sponsors (or if relevant, manufacturers) should notify the Devices Post Market Reforms and Reviews Section of the above matters, together with relevant supporting documents, at postmarketdevices@health.gov.au.

The TGA will take failure to inform it promptly of the above matters into account in deciding whether device entries should be suspended or cancelled.

Version history

Version	Description of change	Author	Effective date
V1.0	Original publication	Devices Post Market Reforms and Reviews Section/Medical Devices Branch	13 October 2020

Therapeutic Goods Administration

PO Box 100 Woden ACT 2606 Australia
Email: info@tga.gov.au Phone: 1800 020 653 Fax: 02 6203 1605
<https://www.tga.gov.au>

Reference/Publication #